Experimental drug aims to boost CAR-T power against lymphoma

NCT ID NCT07361224

Recruiting now Disease control Sponsor: Tel-Aviv Sourasky Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests whether adding a drug called CLS-015 to standard CAR-T cell therapy can help people with large B-cell lymphoma whose disease is stable or getting worse. CLS-015 works by breaking down NETs, which are immune-trapping webs that may block CAR-T cells. The study will enroll 12 adults and focus on safety, not yet on cure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CLS-015 (a drug that breaks down NETs) given alongside CAR-T cell therapy
What this could lead to: If it works, this could improve how well CAR-T therapy fights large B-cell lymphoma, especially in patients whose disease is stable or progressing.
What could go wrong: This is a very early Phase 1 trial with only 12 participants, so safety and effectiveness are not yet proven. The added drug may cause side effects or not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA (LBCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LARGE B-CELL LYMPHOMA (LBCL)

Contacts and locations

Locations

Sourasky Medical Center
RECRUITING

Tel Aviv, 6423906, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.